Leerink Partners analyst Jonathan Chang has maintained their bullish stance on IMTX stock, giving a Buy rating on November 6. Jonathan ...

Immatics (IMTX) has released an update. Immatics is showcasing promising advancements in its TCR-T therapy candidates targeting PRAME, with ...

Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Immatics (IMTX) has released an update. Immatics is showcasing promising advancements in its TCR-T therapy candidates targeting PRAME, with significant responses in metastatic melanoma patients ...

The market expects Immatics (IMTX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...

Immatics (NASDAQ:IMTX – Get Free Report) was the recipient of a significant drop in short interest during the month of September.As of September 30th, there was short interest totalling ...

abrdn plc acquired a new stake in shares of Immatics (NASDAQ:IMTX – Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock To get a sense of who is truly in control of Immatics N.V. (NASDAQ:IMTX), it is ...

Immatics appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ...

Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits ...